JPH0970524A - Permselective separation membrane and method for producing the same - Google Patents
Permselective separation membrane and method for producing the sameInfo
- Publication number
- JPH0970524A JPH0970524A JP8171007A JP17100796A JPH0970524A JP H0970524 A JPH0970524 A JP H0970524A JP 8171007 A JP8171007 A JP 8171007A JP 17100796 A JP17100796 A JP 17100796A JP H0970524 A JPH0970524 A JP H0970524A
- Authority
- JP
- Japan
- Prior art keywords
- weight
- separation membrane
- less
- hydrophilic polymer
- polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- External Artificial Organs (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Abstract
(57)【要約】
【課題】有用蛋白であるアルブミンの透過性を抑え、中
高分子量尿毒蛋白の除去性能を高めた選択透過性分離
膜、および、その製造方法を提供する。
【解決手段】疎水性高分子、親水性高分子を主成分とし
てなる選択透過性分離膜において、分子量10万未満の親
水性高分子が親水性高分子全重量に対して10重量%以
上、50重量%以下含まれ、10万以上の親水性高分子
が親水性高分子全重量に対し、50重量%以上、90重
量%以下含まれていることを特徴とする選択透過性分離
膜。
(57) Abstract: [PROBLEMS] To provide a permselective separation membrane that suppresses the permeability of useful protein albumin and enhances the removal performance of medium and high molecular weight uremic proteins, and a method for producing the same. SOLUTION: In a permselective separation membrane containing a hydrophobic polymer and a hydrophilic polymer as main components, the hydrophilic polymer having a molecular weight of less than 100,000 is 10% by weight or more, based on the total weight of the hydrophilic polymer, 50% or more. A permselective separation membrane characterized by being contained in an amount of 50% by weight or more and 100% or more of a hydrophilic polymer in an amount of 50% by weight or more and 90% by weight or less based on the total weight of the hydrophilic polymer.
Description
【0001】[0001]
【発明の属する技術分野】本発明は選択透過性分離膜お
よびその製造方法に関するものである。さらに詳しくは
膜中に存在する親水性高分子の分子量分布をコントロー
ルすることによって血液処理に用いた場合、高い血液濾
過流量、低アルブミン透過性を長時間にわたって維持
し、中高分子蛋白からなる尿毒物質に対して高い選択透
過性を有する膜ならびに、これらの膜を製造する方法に
関する。TECHNICAL FIELD The present invention relates to a permselective separation membrane and a method for producing the same. More specifically, when it is used for blood treatment by controlling the molecular weight distribution of the hydrophilic polymer present in the membrane, it maintains a high hemofiltration flow rate and low albumin permeability over a long period of time, and is a uremic substance composed of a medium polymer protein. The present invention relates to a membrane having a high selective permeation rate with respect to, and a method for producing these membranes.
【0002】[0002]
【従来の技術】血液処理用の半透膜としては天然素材で
あるセルロース、合成高分子膜素材であるポリスルホ
ン、PMMA、ポリアクリロニトリルなどが今日まで幅
広く使用され、慢性腎不全患者の血液処理法については
人腎に近づけるべく様々な技術開発がなされてきた。近
年、これらの膜素材の中で透析技術の進歩に合致したも
のとして透水性能が高いポリスルホンが注目を浴びてい
る。ポリスルホンは元来、熱可塑性の耐熱性エンジニア
リングプラスチックとして自動車、電気、医療用具の分
野で幅広く用いられているものであるが、ポリスルホン
単体で半透膜を作った場合、分子間凝集力が強く、ま
た、疎水性のために血液との親和性に乏しく、このまま
血液処理用に用いることはできない。従って、孔形成材
として親水性高分子、無機塩などを混入し、溶脱する事
によって孔を形作り、同時にポリマー表面を親水化し、
これを半透膜、逆浸透膜として用いる方法が考案され、
出願されている。2. Description of the Related Art As a semipermeable membrane for blood treatment, natural materials such as cellulose, synthetic polymer membrane materials such as polysulfone, PMMA, and polyacrylonitrile have been widely used until today. Various technological developments have been made to bring humans closer to the human kidney. Among these membrane materials, polysulfone having high water permeability has attracted attention in recent years as one that meets the progress of dialysis technology. Originally, polysulfone is widely used as a thermoplastic heat-resistant engineering plastic in the fields of automobiles, electricity, and medical devices, but when a semipermeable membrane is made of polysulfone alone, the intermolecular cohesive force is strong, Further, since it is hydrophobic, it has a poor affinity with blood and cannot be used as it is for blood treatment. Therefore, by mixing hydrophilic polymer, inorganic salt, etc. as a pore-forming material and leaching to form a pore, at the same time, the surface of the polymer is made hydrophilic.
A method of using this as a semipermeable membrane and a reverse osmosis membrane was devised,
Filed
【0003】血液処理用の半透膜の製造方法としては、
金属塩を入れて製膜する方法、親水性高分子を入れて製
膜する方法、多価アルコールを入れて製膜する方法など
が公開されている。しかし、特開昭61−23286
0、特開昭58−114702のようにポリエチレング
リコール等の多価アルコールを入れて製膜を行う場合、
洗浄が不十分の場合、膜に残存するアルコールによっ
て、透析時に患者の目に異常が起こる。特公平6−75
667ではポリビニルピロリドンを用いる製膜方法も開
示されているが透水性能は高いものの、血液処理用(透
析用)としては、アルブミン透過率が高いという問題が
ある。特開 昭62−121608に示される金属塩を
用いる方法も同様である。特開平6−233921では
高分子量の親水性高分子を入れ、粘度を増加させて原液
の良溶媒を100%芯液として用いることができるよう
にする中空糸膜の製造方法が提案されているが、この方
法では膜のアルブミン透過性をコントロールできない。
また、膜中の親水性高分子の分子量分布についての知見
はない。特公平2−18695ではポリスルホンに対し
高分子量ポリビニルピロリドンの含有率を高く規定し、
ポリビニルピロリドンを膜中に大量に残存させることに
よって膜の耐汚染性、洗浄性を高めた膜が開示されてい
るが、本発明が目的としている高い拡散性能は得られて
いない。さらに特公平5−54373ではポリスルホン
と比較的低分子量のポリビニルピロリドンからなる低粘
度原液を用いて、大部分のポリビニルピロリドンを洗浄
除去した膜が開示されているが本発明のような膜内に残
る親水性高分子の分子量分布が高い拡散性能を発揮する
ことは明記されていない。特に近年透析が始まって20
数年経たことから、長期透析による合併症が数多く報告
され、手根管症候群、その他透析シンドロームの原因物
質として分子量2万から4万の蛋白質が注目を浴びてい
るが、いずれの方法においても前述の蛋白質を積極的に
除去できる高い人腎機能を代替・模倣する選択分離膜は
開示されていない。As a method of manufacturing a semipermeable membrane for blood treatment,
A method of forming a film by adding a metal salt, a method of forming a film by adding a hydrophilic polymer, a method of forming a film by adding a polyhydric alcohol, and the like are disclosed. However, JP-A-61-2286
0, when a polyhydric alcohol such as polyethylene glycol is added to form a film as in JP-A-58-114702,
With insufficient cleaning, residual alcohol on the membrane causes abnormalities in the patient's eye during dialysis. Japanese Patent Fair 6-75
667 also discloses a film forming method using polyvinylpyrrolidone, but although it has high water permeability, it has a problem of high albumin permeability for blood treatment (dialysis). The method using a metal salt disclosed in JP-A-62-121608 is also the same. JP-A-6-233921 proposes a method for producing a hollow fiber membrane in which a hydrophilic polymer having a high molecular weight is added to increase the viscosity so that a good solvent of the stock solution can be used as 100% core liquid. , This method cannot control the albumin permeability of the membrane.
Moreover, there is no knowledge about the molecular weight distribution of the hydrophilic polymer in the film. In Japanese Examined Patent Publication No. 2-18695, the content of high molecular weight polyvinylpyrrolidone is specified to be higher than that of polysulfone.
A film in which a large amount of polyvinylpyrrolidone is left in the film to improve the stain resistance and the cleaning property of the film is disclosed, but the high diffusion performance intended by the present invention has not been obtained. Further, Japanese Patent Publication No. 5-54373 discloses a membrane in which most of polyvinylpyrrolidone is washed and removed using a low-viscosity stock solution of polysulfone and polyvinylpyrrolidone having a relatively low molecular weight, but remains in the membrane as in the present invention. It is not specified that the molecular weight distribution of the hydrophilic polymer exhibits a high diffusion performance. Especially in recent years, dialysis started 20
Since several years have passed, many complications due to long-term dialysis have been reported, and a protein having a molecular weight of 20,000 to 40,000 has been attracting attention as a causative agent of carpal tunnel syndrome and other dialysis syndromes. No selective separation membrane that substitutes or mimics the high human renal function capable of actively removing the protein of the above has not been disclosed.
【0004】[0004]
【発明が解決しようとする課題】本発明者らは、上記欠
点を克服すべく鋭意検討を重ねた結果、本発明を達成す
ることができた。すなわち、有用蛋白であるアルブミン
の透過性を抑え、中高分子量尿毒蛋白の除去性能を高め
た選択透過性分離膜、および、その製造方法を提供する
ことを目的とする。DISCLOSURE OF THE INVENTION As a result of intensive studies conducted by the present inventors to overcome the above drawbacks, the present invention has been accomplished. That is, it is an object of the present invention to provide a permselective separation membrane that suppresses the permeability of albumin, which is a useful protein, and enhances the removal performance of medium and high molecular weight uremic proteins, and a method for producing the same.
【0005】[0005]
【課題を解決するための手段】上記目的を達成するため
に、本願発明は下記の構成を有する。In order to achieve the above object, the present invention has the following constitution.
【0006】「(1) 疎水性高分子、親水性高分子を主成
分としてなる選択透過性分離膜において、分子量10万未
満の親水性高分子が親水性高分子全重量に対して10重
量%以上、50重量%以下含まれ、10万以上の親水性
高分子が親水性高分子全重量に対し、50重量%以上、
90重量%以下含まれていることを特徴とする選択透過
性分離膜。[(1) In a permselective separation membrane composed mainly of a hydrophobic polymer and a hydrophilic polymer, the hydrophilic polymer having a molecular weight of less than 100,000 is 10% by weight based on the total weight of the hydrophilic polymer. As described above, 50% by weight or less is contained, and 100,000 or more hydrophilic polymers are 50% by weight or more based on the total weight of the hydrophilic polymers.
A permselective separation membrane comprising 90% by weight or less.
【0007】(2) 疎水性高分子、親水性高分子を主成分
としてなる選択透過性分離膜において、分子量10万未満
の親水性高分子が親水性高分子全重量に対して10重量
%以上、50重量%以下含まれ、10万以上の親水性高
分子が親水性高分子全重量に対し、50重量%以上、9
0重量%以下含まれた組成物を不溶化処理してなること
を特徴とする選択透過性分離膜。(2) In a permselective separation membrane mainly composed of a hydrophobic polymer and a hydrophilic polymer, the hydrophilic polymer having a molecular weight of less than 100,000 is 10% by weight or more based on the total weight of the hydrophilic polymer. , 50% by weight or less, and 100,000 or more of the hydrophilic polymer is 50% by weight or more based on the total weight of the hydrophilic polymer, 9
A permselective separation membrane, which is obtained by insolubilizing a composition containing 0% by weight or less.
【0008】(3) 疎水性高分子と親水性高分子、溶媒、
添加剤を少なくとも含む製膜原液を用い、分子量10万
以上の親水性高分子の含有比率が該製膜原液全体に対し
て1.8重量%以上、20重量%以下であることを特徴
とする選択透過性分離膜の製造方法。(3) Hydrophobic polymer and hydrophilic polymer, solvent,
A film-forming undiluted solution containing at least an additive is used, and the content ratio of the hydrophilic polymer having a molecular weight of 100,000 or more is 1.8% by weight or more and 20% by weight or less with respect to the entire film-forming undiluted solution. Method for producing permselective separation membrane.
【0009】(4) デキストランによる拡散性能試験にお
いてストークス半径で少なくとも3nmの総括物質移動
係数が0.0025cm/min以上で、かつアルブミ
ン透過率が4%以下である選択透過性分離膜。」(4) A permselective separation membrane having a total mass transfer coefficient of 0.0025 cm / min or more at a Stokes radius of at least 3 nm in a diffusion performance test with dextran and an albumin permeability of 4% or less. "
【0010】[0010]
【発明の実施の態様】本発明において、選択分離膜を形
成するために用いられる原液は疎水性高分子、親水性高
分子、溶媒、および添加剤を少なくとも含有する。BEST MODE FOR CARRYING OUT THE INVENTION In the present invention, the stock solution used for forming a selective separation membrane contains at least a hydrophobic polymer, a hydrophilic polymer, a solvent, and an additive.
【0011】この中で疎水性高分子としては、ポリスル
ホン、ポリアミド、ポリイミド、ポリフェニルエーテ
ル、ポリフェニレンスルフィドなどほとんどのエンジニ
アリングプラスチックを用いることができるが、下記基
本骨格を有するポリスルホンが特に好ましい。下記基本
骨格中、ベンゼン環部分を修飾したものも好ましく用い
ることができる。As the hydrophobic polymer, most engineering plastics such as polysulfone, polyamide, polyimide, polyphenyl ether and polyphenylene sulfide can be used, but polysulfone having the following basic skeleton is particularly preferable. Among the following basic skeletons, those having a modified benzene ring portion can also be preferably used.
【0012】[0012]
【化1】 親水性高分子は、特に限定されるものではないが、疎水
性高分子と溶液中で目には見えないがミクロ相分離構造
を形作るものが好ましく用いられる。具体的には、ポリ
エチレングリコール、ポリビニルアルコール、カルボキ
シメチルセルロース、ポリビニルピロリドンなどがある
が、これらを単独で用いてもよいし、混合して用いても
よい。中でも、工業的に比較的入手しやすい点でポリビ
ニルピロリドンが好ましく用いられる。ここで、親水性
高分子としては、本発明においては分子量が異なる2種
類以上を用いる。分子量分布については特にその比率に
おいて重量平均分子量で5倍以上異なるものを用いるこ
とが好ましい。Embedded image The hydrophilic polymer is not particularly limited, but those which form a microphase-separated structure, which is invisible to the eyes in a solution with the hydrophobic polymer, are preferably used. Specific examples thereof include polyethylene glycol, polyvinyl alcohol, carboxymethyl cellulose, and polyvinylpyrrolidone. These may be used alone or in combination. Among them, polyvinylpyrrolidone is preferably used because it is industrially relatively easy to obtain. Here, as the hydrophilic polymer, two or more kinds having different molecular weights are used in the present invention. With respect to the molecular weight distribution, it is particularly preferable to use one having a weight-average molecular weight that differs by 5 times or more in the ratio.
【0013】溶媒については、疎水性高分子、親水性高
分子、添加剤の3者を良く溶かす両性溶媒が用いられ
る。具体的にはジメチルアセトアミド、ジメチルホルム
アミド、ジメチルスルホキシド、アセトン、アセトアル
デヒド、2ーメチルピロリドンなどであるが、危険性、
安定性、毒性の面からジメチルアセトアミドが好まし
い。 添加剤としては、疎水性高分子の貧溶媒で親水性
高分子と相溶性を持つものが用いられ、具体的には、ア
ルコール、グリセリン、水、エステル類等が挙げられ、
プロセス適性の面から特に水が好ましい。As the solvent, an amphoteric solvent that dissolves well the hydrophobic polymer, the hydrophilic polymer and the additive is used. Specifically, dimethylacetamide, dimethylformamide, dimethylsulfoxide, acetone, acetaldehyde, 2-methylpyrrolidone, etc.
Dimethylacetamide is preferable in terms of stability and toxicity. As the additive, those which are compatible with the hydrophilic polymer in the poor solvent of the hydrophobic polymer are used, and specific examples thereof include alcohol, glycerin, water and esters.
From the viewpoint of process suitability, water is particularly preferable.
【0014】本発明の選択透過性分離膜は、分子量10万
未満の親水性高分子が親水性高分子全重量に対して10
重量%以上、50重量%以下含まれ、かつ10万以上の
親水性高分子が親水性高分子全重量に対し、50重量%
以上、90重量%以下含まれてなる。すなわち本願発明
においては、親水性高分子中、高分子量親水性高分子
に、低分子量親水性高分子が存在することで有用蛋白で
あるアルブミンの透過を抑えつつも中分子領域以上の拡
散性能が特に向上することを見出した。これは、恐ら
く、大きな高分子量ポリマーに低分子のポリマーが入り
込むことによって中分子量蛋白を透過させるべく適当な
網目構造を形成することができるためではないかと考え
られる。これが、高分子量親水性高分子単独の場合、高
透水性能を保ったまま、人工腎臓などに必要な低アルブ
ミン透過性は達成できない。また、低分子量親水性高分
子単独の場合は適当な製膜条件によるポアサイズのコン
トロールが難しく、製膜条件の変更により工程が不安定
となり膜の品位を悪化させるばかりでなく、透水性能を
高くした場合、あるポイントで突然アルブミンのリーク
が起こり、透析用血液処理膜などとして使用することは
不可能となる。In the permselective separation membrane of the present invention, the hydrophilic polymer having a molecular weight of less than 100,000 is contained in the hydrophilic polymer in an amount of 10 or less.
50% by weight or more, and 100,000 or more of hydrophilic polymer is 50% by weight based on the total weight of the hydrophilic polymer.
As described above, the content is 90% by weight or less. That is, in the present invention, in the hydrophilic polymer, in the high molecular weight hydrophilic polymer, the presence of the low molecular weight hydrophilic polymer, while suppressing the permeation of albumin, which is a useful protein, has a diffusion performance in the middle molecular region or higher. It has been found that it is particularly improved. This is probably because a low molecular weight polymer can be incorporated into a large high molecular weight polymer to form an appropriate network structure for permeating a medium molecular weight protein. However, when the high molecular weight hydrophilic polymer is used alone, it is not possible to achieve the low albumin permeability required for artificial kidneys and the like while maintaining high water permeability. Further, when the low molecular weight hydrophilic polymer alone is used, it is difficult to control the pore size by appropriate film forming conditions, and the process becomes unstable due to changes in the film forming conditions, which not only deteriorates the quality of the film but also improves the water permeability. In that case, albumin suddenly leaks at a certain point and cannot be used as a blood treatment membrane for dialysis.
【0015】さらに、選択分離膜中、親水性高分子含有
率が、疎水性高分子に対して、3重量%以上、15重量
%以下であることが好ましい。3重量%未満の場合は水
濡れ性が不十分となる傾向があり、血液と接触した際に
凝固を引き起こす場合があるからである。また、15重
量%を越えると、膜内にある多量の親水性高分子によっ
て、透過性能の低下やアルブミンリークのコントロール
が不十分となる傾向がある。Further, the content of the hydrophilic polymer in the selective separation membrane is preferably 3% by weight or more and 15% by weight or less with respect to the hydrophobic polymer. This is because if it is less than 3% by weight, the wettability tends to be insufficient and coagulation may be caused when contacting blood. On the other hand, if it exceeds 15% by weight, a large amount of the hydrophilic polymer in the membrane tends to reduce the permeation performance and insufficient control of albumin leak.
【0016】また、本発明においては、上記の分子量10
万未満の親水性高分子が親水性高分子全重量に対して1
0重量%以上、50重量%以下含まれ、10万以上の親
水性高分子が親水性高分子全重量に対し、50重量%以
上、90重量%以下含まれている選択分離膜について、
例えば、人工腎臓などに用いる場合には、その親水性高
分子の溶出をできるだけ低減するためには、不溶化処理
することが好ましい。不溶化とは、架橋により、架橋前
のそれぞれのポリマの良溶媒に溶解しなくなることを意
味する。また、不溶化処理後の膜においては、膜全重量
に対し、2重量%以上、15重量%以下の不溶化物を含
むことが好ましい。2重量%未満では、膜内表面近傍の
活性層が薄くなり、例えば、血液処理などに用いた場
合、血液成分の凝集を招く傾向がある。又、15重量%
を越えると、活性層が厚くなりすぎて、透水性能の低下
が起こる場合がある。In the present invention, the above-mentioned molecular weight of 10
Less than 10,000 hydrophilic macromolecules is 1 based on the total weight of hydrophilic macromolecules
A selective separation membrane containing 0% by weight or more and 50% by weight or less and 100,000 or more hydrophilic polymers contained in an amount of 50% by weight or more and 90% by weight or less based on the total weight of the hydrophilic polymer,
For example, when used in an artificial kidney or the like, insolubilization treatment is preferable in order to reduce the elution of the hydrophilic polymer as much as possible. The insolubilization means that the polymer is not dissolved in a good solvent for each polymer before the crosslinking due to the crosslinking. In addition, the film after the insolubilization treatment preferably contains 2% by weight or more and 15% by weight or less of the insoluble matter with respect to the total weight of the film. If it is less than 2% by weight, the active layer in the vicinity of the inner surface of the membrane becomes thin, and when it is used for blood treatment, for example, it tends to cause aggregation of blood components. Also, 15% by weight
If it exceeds, the active layer may become too thick and the water permeability may deteriorate.
【0017】さらに、不溶化物中の由来高分子の比率
は、疎水性高分子が15重量%以上、40重量%以下、
親水性高分子が60重量以上、85重量%以下であるこ
とが好ましい。疎水性高分子が、15重量%未満では、
疎水性基の割合が小さくなり、膜全体の構造が外圧によ
り容易に変化する傾向がある。また、40重量%を越え
ると、逆にしなやかさが少なくなり、膜の糸形状加工
(クリンプ付与など)を行う際に不利な場合がある。Further, the ratio of the derived polymer in the insolubilized product is such that the hydrophobic polymer is 15% by weight or more and 40% by weight or less,
The hydrophilic polymer content is preferably 60% by weight or more and 85% by weight or less. If the hydrophobic polymer is less than 15% by weight,
The proportion of hydrophobic groups becomes small, and the structure of the entire membrane tends to change easily due to external pressure. On the other hand, if it exceeds 40% by weight, on the other hand, the flexibility is reduced, which may be disadvantageous when performing thread shape processing (crimping etc.) of the film.
【0018】不溶化方法としては、限定されるものでは
ないが、例えばγ線、電子線、熱、化学的方法などによ
り、架橋を行うことが好ましい。特に、水の存在下での
γ線照射が好ましく、照射量は10〜50KGy、さら
には20〜40KGyであることが好ましい。不溶化橋
処理により、疎水性高分子と親水性高分子が結合し、親
水性高分子の溶出が減少する。また、このような処理を
行うと性能、構造に変化が生じると考えられるが中高分
子量蛋白を積極的に透過させる網目構造は架橋処理によ
って構造が保持、補強されるため若干の性能低下は見ら
れるもののほとんど変化しない。The insolubilization method is not limited, but it is preferable to carry out the crosslinking by, for example, γ-ray, electron beam, heat, chemical method or the like. In particular, γ-ray irradiation in the presence of water is preferable, and the irradiation amount is preferably 10 to 50 KGy, more preferably 20 to 40 KGy. By the insolubilization bridge treatment, the hydrophobic polymer and the hydrophilic polymer are bound to each other, and the elution of the hydrophilic polymer is reduced. In addition, although it is considered that such treatment causes changes in performance and structure, the network structure that positively permeates medium- and high-molecular-weight proteins shows some deterioration in performance because the structure is retained and reinforced by the crosslinking treatment. However, it hardly changes.
【0019】本発明において、選択分離膜中、疎水性高
分子、親水性高分子が含まれていることは、固体13C
−NMRスペクトル分析により分析可能である。又、疎
水性高分子、親水性高分子の含有量は、元素分析により
分析可能である。In the present invention, the fact that a hydrophobic polymer or a hydrophilic polymer is contained in the selective separation membrane means that it is a solid 13C.
-It can be analyzed by NMR spectrum analysis. The content of the hydrophobic polymer and the hydrophilic polymer can be analyzed by elemental analysis.
【0020】本発明においては、疎水性高分子、親水性
高分子、溶媒、添加剤を少なくとも含む製膜原液を用
い、分子量の異なる親水性高分子を2種類以上含有し、
かつ、分子量10万以上の親水性高分子の含有比率を該
製膜原液全体に対して1.8重量%以上、20重量%以
下とすることにより、本願発明の選択分離膜を得ること
ができる。20重量%を越えると、原液粘度が上昇し、
製膜困難となり、又、透水性、拡散性能が低下する。一
方、1.8重量%未満であると、中高分子尿毒蛋白を透
過させるための適当な網目構造を構築できない。In the present invention, a film-forming stock solution containing at least a hydrophobic polymer, a hydrophilic polymer, a solvent and an additive is used, and two or more hydrophilic polymers having different molecular weights are contained,
Further, the selective separation membrane of the present invention can be obtained by setting the content ratio of the hydrophilic polymer having a molecular weight of 100,000 or more to 1.8% by weight or more and 20% by weight or less with respect to the entire membrane forming solution. . If it exceeds 20% by weight, the viscosity of the stock solution increases,
It becomes difficult to form a film, and the water permeability and the diffusion performance are deteriorated. On the other hand, if the amount is less than 1.8% by weight, an appropriate network structure for permeating the medium and high molecular weight uremic protein cannot be constructed.
【0021】高分子量の親水性高分子を添加することに
よる原液安定性については次の様に説明できる。添加剤
は、共存する親水性高分子との分子間力により包接さ
れ、疎水性高分子と直接接触することはない。しかし、
溶解中の高温のために、一部が離脱を起こし、そのため
に、疎水性高分子の2量体などのオリゴマーの再結晶化
を促し、原液が白濁を起こす要因となる。親水性高分子
の分子量が高くなるほど包接効果が増大するため、原液
の安定性が改善される効果を生む。また、原液粘度は、
親水性高分子の分子量に依存するが、当然ながら原液粘
度の低下はその中空糸製膜時に糸切れ、糸揺れなどを起
こし安定性を悪化させる。この点でも、親水性高分子の
混合系において平均分子量を上げることは重要である。The stability of the stock solution by adding a high molecular weight hydrophilic polymer can be explained as follows. The additive is clathrated by the intermolecular force with the coexisting hydrophilic polymer and does not come into direct contact with the hydrophobic polymer. But,
Due to the high temperature during the dissolution, a part is detached, which promotes the recrystallization of oligomers such as a dimer of the hydrophobic polymer, which causes the stock solution to become cloudy. As the molecular weight of the hydrophilic polymer increases, the inclusion effect increases, so that the stability of the stock solution is improved. The stock solution viscosity is
Although it depends on the molecular weight of the hydrophilic polymer, naturally, the decrease in the viscosity of the stock solution causes yarn breakage, yarn sway, and the like at the time of forming the hollow fiber to deteriorate the stability. Also in this respect, it is important to increase the average molecular weight in the mixed system of hydrophilic polymers.
【0022】次に製膜原液のポリマー濃度について述べ
る。前述の点からポリマー濃度は上げるに従って製膜性
は良くなるが逆に空孔率が減少し、透水性能が低下する
ため最適範囲が存在する。ゆえに、疎水性高分子の濃度
は10〜30重量%、好ましくは15〜25重量%、親
水性高分子の濃度は2〜20重量%、好ましくは3〜1
5重量%である。Next, the polymer concentration of the stock solution for film formation will be described. From the above-mentioned point, as the polymer concentration is increased, the film-forming property is improved, but on the contrary, the porosity is reduced and the water permeability is reduced, so that an optimum range exists. Therefore, the concentration of the hydrophobic polymer is 10 to 30% by weight, preferably 15 to 25% by weight, and the concentration of the hydrophilic polymer is 2 to 20% by weight, preferably 3 to 1%.
5% by weight.
【0023】本願発明の選択分離膜の製造方法として、
一例を以下に説明する。As the method for producing the selective separation membrane of the present invention,
An example will be described below.
【0024】上記のような製膜原液を、芯液と同時に2
重スリット管構造の口金から同時に吐出させ、中空糸膜
を成形する。その後、所定の水洗、保湿工程を経た後、
巻き取られる。更に、例えば、人工腎臓などに用いられ
る場合には、モジュール化され、水充填し、架橋される
ことが好ましい。[0024] The above-mentioned stock solution for film formation was used at the same time as the core liquid.
The hollow fiber membrane is formed by discharging simultaneously from the die of the heavy slit tube structure. Then, after undergoing a predetermined water washing and moisturizing process,
Being rolled up. Furthermore, for example, when it is used for an artificial kidney or the like, it is preferably modularized, filled with water, and crosslinked.
【0025】更に、本願発明の選択透過性分離膜は、デ
キストランによる実施例において述べる拡散性能試験に
おいて、少なくとも3nmの総括物質移動係数が0.0
025cm/min以上で、かつアルブミン透過率が4
%以下となる。アルブミン透過率は、更に、3%以下、
2%以下であることが好ましい。Furthermore, the permselective separation membrane of the present invention has an overall mass transfer coefficient of 0.0 at least 3 nm in the diffusion performance test described in the examples with dextran.
025 cm / min or more and albumin permeability of 4
% Or less. Albumin permeability is 3% or less,
It is preferably 2% or less.
【0026】本発明において、選択透過性分離膜の形態
としては、平膜、中空糸膜等、特に限定されるものでは
ない。In the present invention, the form of the permselective separation membrane is not particularly limited, such as a flat membrane and a hollow fiber membrane.
【0027】本発明により得られた選択透過性分離膜
は、人工腎臓、人工肝臓、エンドトキシンフィルター、
バイオリアクター等の医療用途、水処理等、各種用途に
用いることができる。The permselective separation membrane obtained by the present invention is an artificial kidney, an artificial liver, an endotoxin filter,
It can be used for various applications such as medical applications such as bioreactors and water treatment.
【0028】[0028]
【実施例】次に実施例に基づきに本発明を説明する。EXAMPLES The present invention will now be described based on examples.
【0029】用いた測定法は以下の通りである。The measuring method used is as follows.
【0030】(1)透水性能の測定中空糸両端部を封止
したモジュール(面積 1.6m2 )の中空糸内側に水
圧100mmHgをかけ、外側へ流出してくる単位時間
当たりの濾過量を測定した。透水性能は下記の式で算出
した。(1) Measurement of water permeability Performance of the module (area: 1.6 m 2 ) in which both ends of the hollow fiber are sealed is applied with a water pressure of 100 mmHg on the inside of the hollow fiber, and the amount of filtration per unit time flowing out to the outside is measured. did. The water permeability was calculated by the following equation.
【0031】 UFR(ml/hr/m2 /mmHg )=QW /(P×T×A) ここでQW :濾過量(ml)、T:流出時間(hr)、
P:圧力(mmHg)、A:膜面積(m2 )(中空糸
内表面面積換算)を示す。UFR (ml / hr / m 2 / mmHg) = Q W / (P × T × A) where Q W : filtration amount (ml), T: outflow time (hr),
P: pressure (mmHg), A: membrane area (m 2 ) (in terms of hollow fiber inner surface area).
【0032】(2)デキストランによる拡散性能測定 基本的には透析性能測定法と同様に行った。その概要を
示す。分子量分布の異なるデキストラン(FULKA社
製 平均分子量〜1200,〜6000,15000〜
20000,40000,56000,222000)
を0.5mg/mlになるように限外濾過水に溶解し
た。この溶液を37℃に加熱、保温し、血液側(中空糸
内側)にポンプで流量200ml/minで送り、透析
液側は血液側と向流となるように限外濾過水を37℃に
保ったものを500ml/minで送った。ここで、注
意することは濾過圧力がゼロになるように調整すること
である。すなわち、限外濾過が生じない条件で膜の拡散
性能を測定することである。平衡状態になるまで20分
送り続け、その後、血液側入り口、出口、透析側をサン
プリングした。サンプリングした溶液を細孔径0.5ミ
クロンのフィルターで濾過を行った。その溶液をゲル透
過クロマトグラフィー用カラム(東ソー TSKge
l G3000PW)、カラム温度40℃、移動相を液
クロ用純水、1ml/min、サンプル打ち込み量50
μlで分析を行い、血液側の入り口、出口の濃度変化に
よってモジュールの総括物質移動係数を求めた。なお、
測定前に、単分散の5種類のデキストランを用いてカラ
ムのキャリブレーションを行った。総括物質移動係数は
以下の式を用いて算出した。(2) Measurement of diffusion performance with dextran Basically, the measurement was performed in the same manner as the dialysis performance measurement method. The outline is shown below. Dextran with different molecular weight distribution (average molecular weight manufactured by FULKA ~ 1200, ~ 6000,15000 ~
20000, 40000, 56000, 222000)
Was dissolved in ultrafiltered water to a concentration of 0.5 mg / ml. This solution is heated to 37 ° C and kept warm, pumped to the blood side (inside the hollow fiber) at a flow rate of 200 ml / min, and the ultrafiltrated water is kept at 37 ° C so that the dialysate side is countercurrent to the blood side. Was sent at 500 ml / min. Here, it should be noted that the filtration pressure should be adjusted to zero. That is, the diffusion performance of the membrane is measured under the condition that ultrafiltration does not occur. The feeding was continued for 20 minutes until the equilibrium state was reached, and then the blood side inlet, outlet, and dialysis side were sampled. The sampled solution was filtered with a filter having a pore size of 0.5 micron. The solution was used as a column for gel permeation chromatography (Tosoh TSKge
G3000PW), column temperature 40 ° C., mobile phase pure water for liquid chromatography, 1 ml / min, sample injection amount 50
Analysis was carried out in μl, and the overall mass transfer coefficient of the module was determined by the concentration changes at the inlet and outlet on the blood side. In addition,
Prior to the measurement, the column was calibrated using 5 kinds of monodisperse dextran. The overall mass transfer coefficient was calculated using the following formula.
【0033】クリアランスClearance
【化2】 ここでCBi:モジュール入口側濃度、CBo:モジュ
ール出口側濃度、QB:モジュール供給液量(ml/m
in)を示す。Embedded image Here, CBi: module inlet side concentration, CBo: module outlet side concentration, QB: module supply liquid amount (ml / m
in) is shown.
【0034】[0034]
【化3】 ここでAは面積(m2 )を示す。Embedded image Here, A represents an area (m 2 ).
【0035】ストークス半径は文献{J.Brandr
up,E.H.Immergut”Polymer H
andbook” (1989)、〓112〜113頁
John Wiley&Sons,inc}、{人工臓
器13巻6号(1984)23〜30頁}に基づいて下
記式にて計算した。ストークス半径(nm)=0.04
456×(デキストラン分子量)0.43821 (3)アルブミン透過率の測定 血液槽に温度37℃で保温したヘマトクリット30%、
総蛋白量6.5g/dlの牛血(ヘパリン処理血)を用
いて、中空糸内側にポンプで200ml/minで送っ
た。その際、モジュール出口側の圧力を調整して、濾過
量がモジュール面積1m2 当たり20ml/min(す
なわち1.6m2 では32ml/min)かかるように
し、濾液、出口血液は血液槽に戻した。環流開始後1時
間後に中空糸側入り口、出口の血液、濾液をサンプリン
グし、血液側をBCG法、濾液側をCBB法キット(和
光純薬)によって分析し、その濃度からアルブミン透過
率(%)を算出した。The Stokes radius is described in the literature {J. Brandr
up, E .; H. Imergut "Polymer H
and book "(1989), pp. 112-113, John Wiley & Sons, inc}, {Artificial Organ 13: 6 (1984) 23-30}. Stokes radius (nm) = 0. 04
456 x (dextran molecular weight) 0.43821 (3) Measurement of albumin permeability Hematocrit 30% kept at 37 ° C in a blood tank,
Bovine blood (heparin-treated blood) having a total protein amount of 6.5 g / dl was used to pump the inside of the hollow fiber at a rate of 200 ml / min using a pump. At that time, the pressure at the module outlet side was adjusted so that the filtration amount was 20 ml / min per 1 m 2 of the module area (that is, 32 ml / min at 1.6 m 2 ), and the filtrate and the outlet blood were returned to the blood tank. One hour after the start of the reflux, blood and filtrate at the inlet and outlet of the hollow fiber were sampled, and the blood side was analyzed by a BCG method and the filtrate side was analyzed by a CBB method kit (Wako Pure Chemical Industries), and albumin transmittance (%) was determined from the concentration. Was calculated.
【0036】[0036]
【化4】 ここでCF:濾液中、CBi:モジュール入り口、 C
Bi:モジュール出口のアルブミン濃度を示す。Embedded image Here, CF: in the filtrate, CBi: module inlet, C
Bi: The albumin concentration at the module outlet is shown.
【0037】(4)ゲル透過クロマトグラフィーによる
ポリビニルピロリドン分子量分布の測定 所定の凝固水洗工程を経た中空糸100mgをγ線照射
前に塩化メチレン5mgに溶解し、塩存在下で水抽出を
行い、得られた水溶液を超遠心機(20000rpm×
10min)で分離し、水層を細孔径0.5ミクロンの
フィルターで濾過を行いサンプル液とした。この溶液を
温度23℃で東ソーTSK−gel−GMPWx1 2
本直列につないだ理論段数(8900段)のカラムを用
い、移動相として0.08M−トリス緩衝液(pH7.
9)、流量 1.0ml/min、サンプル打ち込み量
0.3mlで分析を行った。5種の単分散ポリエチレ
ングリコールを基準物質にして分子量分布を求めた。(4) Measurement of Polyvinylpyrrolidone Molecular Weight Distribution by Gel Permeation Chromatography 100 mg of the hollow fiber which has undergone a predetermined coagulation and water washing step is dissolved in 5 mg of methylene chloride before γ-irradiation, and water extraction is carried out in the presence of salt to obtain The resulting aqueous solution is ultracentrifuged (20,000 rpm x
After separation for 10 min), the aqueous layer was filtered with a filter having a pore size of 0.5 micron to obtain a sample liquid. Tosoh TSK-gel-GMPWx1 2
A column having the theoretical plate number (8900 plates) connected in series was used, and 0.08 M Tris buffer (pH 7.
9), the flow rate was 1.0 ml / min, and the sample injection amount was 0.3 ml. The molecular weight distribution was determined using 5 kinds of monodisperse polyethylene glycol as reference substances.
【0038】(5)紡糸原液中のポリビニルピロリドン
の重量平均分子量 紡糸原液中のポリビニルピロリドンの重量平均分子量は
K値と光散乱法によって求めた重量平均分子量の相関曲
線から換算した。BASF社の技術情報文献”Koll
idon :Polyvinylpyrrolidon
e for Pharmaceutical indu
stry” のFig.15から重量平均分子量とK値
との関係において下記の式を用いて計算した。重量平均
分子量(Mw)= exp1.055495×K2.871682 (6)元素分析法によるポリビニルピロリドンの含有率
の測定 γ線照射後のサンプルを常温、真空ポンプで乾固させ、
その10mgをCHNコーダーで分析し、窒素含有量か
らポリビニルピロリドンの含有率を計算した。 (7)項で得られた不溶化物も同様に測定し、ポリビニ
ルピロリドン、ポリスルホン由来の組成含有率を計算し
た。(5) Weight average molecular weight of polyvinylpyrrolidone in spinning dope The weight average molecular weight of polyvinylpyrrolidone in the spinning dope was calculated from the correlation curve between the K value and the weight average molecular weight determined by the light scattering method. BASF's technical information document "Koll
idon: Polyvinylpyrrolidone
e for Pharmaceutical indu
The weight average molecular weight and the K value were calculated using the following formula from “Stry” FIG. 15. Weight average molecular weight (Mw) = exp 1.055495 × K 2.871682 (6) Content of polyvinylpyrrolidone by elemental analysis Measurement of the sample after γ-ray irradiation is dried at room temperature with a vacuum pump,
10 mg thereof was analyzed with a CHN coder, and the content of polyvinylpyrrolidone was calculated from the nitrogen content. The insoluble matter obtained in the item (7) was also measured in the same manner, and the composition content derived from polyvinylpyrrolidone and polysulfone was calculated.
【0039】(7)不溶物量の測定 γ線照射後の中空糸膜10gを取り、100mlのジメ
チルホルムアミドに溶解した。遠心分離機で1500r
pm 10分で不溶物を分離し、上澄み液を捨てる。こ
の操作を3回繰り返し、残った固形物を蒸発乾固し、そ
の重量から不溶物の含有率を求めた。(7) Measurement of insoluble matter amount 10 g of the hollow fiber membrane after γ-ray irradiation was taken and dissolved in 100 ml of dimethylformamide. 1500r with centrifuge
Insoluble matter is separated at pm for 10 minutes, and the supernatant is discarded. This operation was repeated 3 times, the remaining solid matter was evaporated to dryness, and the content of the insoluble matter was determined from its weight.
【0040】実施例1 ポリスルホン(アモコ社 Udel−P3500)18
部、ポリビニルピロリドン(BASF K90)3部、
ポリビニルピロリドン(BASF K30)6部をジメ
チルアセトアミド72部、水1部に加え、加熱溶解し、
製膜原液とした。原液粘度は30℃で70ポイズであっ
た。この原液を温度50℃の紡糸口金部へ送り、外径
0.3mm、内径0.2mmの2重スリット管から芯液
としてジメチルアセトアミド65部、水35部からなる
溶液を吐出させ中空糸膜を形成させた後、温度30℃、
露点28℃の調湿250mmのドライゾーン雰囲気を経
て、ジメチルアセトアミド20wt%、水80wt%か
らなる温度40℃の凝固浴を通過させ、80℃20秒の
水洗工程、グリセリンによる保湿工程を経て得られた中
空糸膜を巻き取り束とした。この中空糸膜を1.6m2
になるように、ケースに充填し、ポッティングしてモジ
ュールとした。次に、γ線照射前にゲル透過クロマトグ
ラフィー法による中空糸残存ポリビニルピロリドンの分
子量分布を調べた結果、分子量10万未満が27%、1
0万以上が73%であった。また、γ線照射前のモジュ
ールについて総括物質移動係数(Ko)を測定した結
果、ストークス半径4.5nmで0.0025cm/m
in、透水性能 980ml/hr/m2 /mmHg、
アルブミン透過率1.4%であった。γ線照射後、同様
に総括物質移動係数(Ko)及び水濾過性能、アルブミ
ン透過率を測定したところKoはストークス半径4nm
で0.0025cm/min、透水性能 1000ml
/hr/m2 /mmHg、アルブミン透過率1.5%で
あった。 さらに、中空糸膜中のポリビニルピロリドン
量を元素分析法により測定したところ8%であった。ま
た、γ線照射後の中空糸の不溶物量を測定したところ1
1%であった。不溶化物の組成を調べたところポリスル
ホン由来26%、ポリビニルピロリドン由来74%であ
った。Example 1 Polysulfone (Udel-P3500, Amoco) 18
Parts, polyvinylpyrrolidone (BASF K90) 3 parts,
Add 6 parts of polyvinylpyrrolidone (BASF K30) to 72 parts of dimethylacetamide and 1 part of water, heat and dissolve,
It was used as a film forming stock solution. The stock viscosity was 70 poise at 30 ° C. This stock solution was sent to a spinneret part at a temperature of 50 ° C., and a solution consisting of 65 parts of dimethylacetamide as a core liquid and 35 parts of water was discharged as a core liquid from a double slit tube having an outer diameter of 0.3 mm and an inner diameter of 0.2 mm to form a hollow fiber membrane. After forming, temperature 30 ℃,
It was obtained by passing through a coagulation bath of 20 wt% dimethylacetamide and 80 wt% of water at a temperature of 40 ° C. through a dry zone atmosphere with a dew point of 28 ° C. and a humidity of 250 mm, followed by a washing process at 20 ° C. for 20 seconds and a moisturizing process with glycerin. The hollow fiber membranes were wound into a bundle. 1.6 m 2 of this hollow fiber membrane
Was filled into a case and potted to obtain a module. Next, as a result of examining the molecular weight distribution of the hollow fiber residual polyvinylpyrrolidone by gel permeation chromatography before γ-irradiation, a molecular weight of less than 100,000 was 27%, 1
73% was over 100,000. The overall mass transfer coefficient (Ko) of the module before γ-ray irradiation was measured, and as a result, it was 0.0025 cm / m at a Stokes radius of 4.5 nm.
in, water permeability 980 ml / hr / m 2 / mmHg,
The albumin transmittance was 1.4%. After γ-ray irradiation, the overall mass transfer coefficient (Ko), water filtration performance, and albumin permeability were measured in the same manner, and Ko was found to have a Stokes radius of 4 nm.
0.0025cm / min, water permeability 1000ml
/ Hr / m 2 / mmHg, albumin permeability was 1.5%. Furthermore, the amount of polyvinylpyrrolidone in the hollow fiber membrane was 8% when measured by an elemental analysis method. In addition, when the amount of insoluble matter in the hollow fiber after γ-ray irradiation was measured, it was 1
It was 1%. When the composition of the insoluble matter was examined, it was 26% derived from polysulfone and 74% derived from polyvinylpyrrolidone.
【0041】実施例2 ポリスルホン(アモコ社 Udel−P3500)18
部、ポリビニルピロリドン(BASF K90)4部、
ポリビニルピロリドン(BASF K30)5部をジメ
チルアセトアミド72部、水1部に加え、加熱溶解し製
膜原液とした。原液粘度は30℃で120ポイズであっ
た。実施例1と同様な工程を経てモジュール化した。次
に、γ線照射前にゲル透過クロマトグラフィー法による
中空糸残存ポリビニルピロリドンの分子量分布を調べた
結果、分子量10万未満が35%、10万以上が65%
であった。Example 2 Polysulfone (Amoco Udel-P3500) 18
Parts, polyvinylpyrrolidone (BASF K90) 4 parts,
5 parts of polyvinylpyrrolidone (BASF K30) was added to 72 parts of dimethylacetamide and 1 part of water, and dissolved by heating to obtain a film forming stock solution. The stock viscosity was 120 poise at 30 ° C. The module was formed through the same steps as in Example 1. Next, as a result of examining the molecular weight distribution of the polyvinylpyrrolidone remaining in the hollow fiber by the gel permeation chromatography method before γ-irradiation, the molecular weight of less than 100,000 was 35% and 100,000 or more was 65%.
Met.
【0042】γ線照射後、総括物質移動係数(Ko)及
び水濾過性能、アルブミン透過率を測定したところKo
はストークス半径3.3nmで0.0025cm/mi
n、透水性能 800ml/hr/m2 /mmHg、ア
ルブミン透過率2.0%であった。さらに、中空糸膜中
のポリビニルピロリドン量を元素分析法により測定した
ところ9%であった。また、γ線照射後の中空糸の不溶
物量を測定したところ12%となった。不溶化物の組成
を調べたところポリスルホン由来20%、ポリビニルピ
ロリドン由来80%であった。After γ-irradiation, the overall mass transfer coefficient (Ko), water filtration performance and albumin permeability were measured and found to be Ko.
Is 0.0025 cm / mi with a Stokes radius of 3.3 nm
n, water permeability 800 ml / hr / m 2 / mmHg, albumin permeability 2.0%. Further, the amount of polyvinylpyrrolidone in the hollow fiber membrane was measured by elemental analysis, and was found to be 9%. The amount of insoluble matter in the hollow fiber after γ-ray irradiation was measured and found to be 12%. When the composition of the insoluble matter was examined, it was 20% derived from polysulfone and 80% derived from polyvinylpyrrolidone.
【0043】実施例3 ポリスルホン(アモコ社 Udel−P3500)18
部、ポリビニルピロリドン(BASF K60)9部を
ジメチルアセトアミド72部、水1部に加え、加熱溶解
し製膜原液とした。原液粘度は30℃で100ポイズで
あった。実施例1と同様な工程を経てモジュール化し
た。次に、γ線照射前にゲル透過クロマトグラフィー法
による中空糸残存ポリビニルピロリドンの分子量分布を
調べた結果、分子量10万未満が40%、10万以上が
60%であった。Example 3 Polysulfone (Amoco Udel-P3500) 18
And 9 parts of polyvinylpyrrolidone (BASF K60) were added to 72 parts of dimethylacetamide and 1 part of water, and dissolved by heating to prepare a stock solution for film formation. The stock viscosity was 100 poise at 30 ° C. The module was formed through the same steps as in Example 1. Next, as a result of examining the molecular weight distribution of the polyvinylpyrrolidone remaining in the hollow fibers by gel permeation chromatography before γ-irradiation, the molecular weight was 40% for less than 100,000 and 60% for 100,000 or more.
【0044】γ線照射後、総括物質移動係数(Ko)及
び水濾過性能、アルブミン透過率を測定したところKo
はストークス半径3.5nmで0.0025cm/mi
n、透水性能 500ml/hr/m2 /mmHg、ア
ルブミン透過率1.8%であった。さらに、中空糸膜中
のポリビニルピロリドン量を元素分析法により測定した
ところ5%であった。また、γ線照射後の中空糸の不溶
物量を測定したところ10%となった。不溶化物の組成
を調べたところポリスルホン由来15%、ポリビニルピ
ロリドン由来85%であった。After γ-irradiation, the overall mass transfer coefficient (Ko), water filtration performance and albumin permeability were measured and found to be Ko.
Is 0.0025 cm / mi with a Stokes radius of 3.5 nm
n, water permeability 500 ml / hr / m 2 / mmHg, albumin permeability 1.8%. Further, the amount of polyvinylpyrrolidone in the hollow fiber membrane was measured by elemental analysis and found to be 5%. Further, the amount of insoluble matter in the hollow fiber after γ-ray irradiation was measured and found to be 10%. When the composition of the insoluble matter was examined, it was 15% derived from polysulfone and 85% derived from polyvinylpyrrolidone.
【0045】比較例1 ポリスルホン(アモコ社 Udel−P3500)18
部、ポリビニルピロリドン(BASF K90)1.5
部、ポリビニルピロリドン(BASF K30)7.5
部をジメチルアセトアミド72部、水1部に加え、加熱
溶解し、製膜原液とした。原液粘度は30℃で60ポイ
ズであった。実施例1に従って製膜し、モジュール化し
た。次に、γ線照射前にゲル透過クロマトグラフィー法
による中空糸残存ポリビニルピロリドンの分子量分布を
調べた結果、分子量10万未満が60%、10万以上が
40%であった。Comparative Example 1 Polysulfone (Amoco Udel-P3500) 18
Part, polyvinylpyrrolidone (BASF K90) 1.5
Parts, polyvinylpyrrolidone (BASF K30) 7.5
Parts to 72 parts of dimethylacetamide and 1 part of water, and dissolved by heating to obtain a film-forming stock solution. The stock solution viscosity was 60 poise at 30 ° C. A film was formed according to Example 1 and modularized. Next, the molecular weight distribution of the polyvinylpyrrolidone remaining in the hollow fiber was examined by gel permeation chromatography before γ-ray irradiation. As a result, the molecular weight was less than 100,000, 60%, and 100,000 or more, 40%.
【0046】γ線照射後、総括物質移動係数(Ko)及
び水濾過性能、アルブミン透過率を測定したところKo
はストークス半径2.5nmでKoが0.0025cm
/min、透水性能 600ml/hr/m2 /mmH
g、アルブミン透過率0.5%であった。さらに、中空
糸膜中のポリビニルピロリドン量を元素分析法により測
定したところ4%であった。また、γ線照射後の中空糸
の不溶物量を測定したところ0.15%となった。不溶
化物の組成を調べたところポリスルホン由来10%、ポ
リビニルピロリドン由来90%であった。After γ-irradiation, the overall mass transfer coefficient (Ko), water filtration performance and albumin permeability were measured and found to be Ko.
Has a Stokes radius of 2.5 nm and Ko of 0.0025 cm
/ Min, water permeability 600ml / hr / m 2 / mmH
g, albumin transmittance was 0.5%. Furthermore, the amount of polyvinylpyrrolidone in the hollow fiber membrane was 4% when measured by an elemental analysis method. Further, the amount of insoluble matter in the hollow fiber after γ-ray irradiation was measured and found to be 0.15%. When the composition of the insoluble matter was examined, it was 10% derived from polysulfone and 90% derived from polyvinylpyrrolidone.
【0047】比較例2 ポリスルホン(アモコ社 Udel−P3500)18
部、ポリビニルピロリドン(BASF K90)7部を
ジメチルアセトアミド74部、水1部に加え、加熱溶解
し製膜原液とした。原液粘度は30℃で250ポイズで
あった。実施例1に従って製膜し、モジュール化した。
次に、γ線照射前にゲル透過クロマトグラフィー法によ
る中空糸残存ポリビニルピロリドンの分子量分布を調べ
た結果、分子量10万未満が8%、10万以上が92%
であった。Comparative Example 2 Polysulfone (Udel-P3500, Amoco) 18
Parts, and 7 parts of polyvinylpyrrolidone (BASF K90) were added to 74 parts of dimethylacetamide and 1 part of water and dissolved by heating to give a stock solution for film formation. The stock solution viscosity was 250 poise at 30 ° C. A film was formed according to Example 1 and modularized.
Next, as a result of examining the molecular weight distribution of the polyvinylpyrrolidone remaining in the hollow fiber by gel permeation chromatography before γ-irradiation, a molecular weight of less than 100,000 was 8% and 100,000 or more was 92%.
Met.
【0048】γ線照射後、総括物質移動係数(Ko)及
び水濾過性能、アルブミン透過率を測定したところKo
はストークス半径2.8nmで0.0025cm/mi
n、透水性能120ml/hr/m2 /mmHg、アル
ブミン透過率4.5%であった。さらに、中空糸膜中の
ポリビニルピロリドン量を元素分析法により測定したと
ころ16%であった。また、γ線照射後の中空糸の不溶
物量を測定したところ20%となった。不溶化物の組成
を調べたところポリスルホン由来4%、ポリビニルピロ
リドン由来96%であった。After γ-ray irradiation, the overall mass transfer coefficient (Ko), water filtration performance, and albumin permeability were measured and found to be Ko.
Is 0.0025 cm / mi with Stokes radius of 2.8 nm
n, water permeability of 120 ml / hr / m 2 / mmHg, and albumin permeability of 4.5%. Furthermore, the amount of polyvinylpyrrolidone in the hollow fiber membrane was 16% when measured by an elemental analysis method. Further, the amount of insoluble matter in the hollow fiber after γ-ray irradiation was measured and found to be 20%. When the composition of the insoluble matter was examined, it was 4% derived from polysulfone and 96% derived from polyvinylpyrrolidone.
【0049】比較例3 ポリスルホン(アモコ社 Udel−P3500)18
部、ポリビニルピロリドン(BASF K30)9部を
ジメチルアセトアミド72部、水1部に加え、加熱溶解
し、製膜原液とした。原液粘度は30℃で30ポイズで
あった。実施例1に従って製膜し、モジュール化した。
次に、γ線照射前にゲル透過クロマトグラフィー法によ
る中空糸残存ポリビニルピロリドンの分子量分布を調べ
た結果、分子量10万未満が80%、10万以上が20
%であった。Comparative Example 3 Polysulfone (Udel-P3500, Amoco) 18
And 9 parts of polyvinylpyrrolidone (BASF K30) were added to 72 parts of dimethylacetamide and 1 part of water, and dissolved by heating to obtain a film forming stock solution. The stock solution viscosity was 30 poise at 30 ° C. A film was formed according to Example 1 and modularized.
Next, the molecular weight distribution of the polyvinylpyrrolidone remaining in the hollow fiber was examined by gel permeation chromatography before γ-ray irradiation. As a result, a molecular weight of less than 100,000 was 80%, and 100,000 or more was 20.
%Met.
【0050】γ線照射後、総括物質移動係数(Ko)及
び水濾過性能、アルブミン透過率を測定したところKo
はストークス半径2.8nmで0.0025cm/mi
n、透水性能710ml/hr/m2 /mmHg、アル
ブミン透過率0.02%であった。さらに、中空糸膜中
のポリビニルピロリドン量を元素分析法により測定した
ところ4%であった。また、γ線照射後の中空糸の不溶
物量を測定したところ0.5%となった。不溶化物の組
成を調べたところポリスルホン由来42%、ポリビニル
ピロリドン由来58%であった。After γ-ray irradiation, the overall mass transfer coefficient (Ko), water filtration performance, and albumin permeability were measured and found to be Ko.
Is 0.0025 cm / mi with Stokes radius of 2.8 nm
n, water permeability 710 ml / hr / m 2 / mmHg, albumin permeability 0.02%. Furthermore, the amount of polyvinylpyrrolidone in the hollow fiber membrane was 4% when measured by an elemental analysis method. Further, the amount of insoluble matter in the hollow fiber after γ-ray irradiation was measured and found to be 0.5%. When the composition of the insoluble matter was examined, it was 42% derived from polysulfone and 58% derived from polyvinylpyrrolidone.
【0051】[0051]
【発明の効果】選択透過性分離膜に存在する親水性高分
子の分子量分布をコントロールすることによって例えば
医療分野に用いた場合、低分子から中高分子領域全般に
優れた尿毒物質拡散性能を維持しつつ、アルブミン透過
性を抑えることが出来るため、血液透析、血液濾過、血
液透析濾過等に利用した場合、腎不全患者の病体改善に
良い治療成績が期待できる。また、高透水性能を活かし
て透析液浄化のためのエンドトキシン除去フィルターな
どに適用可能である。By controlling the molecular weight distribution of the hydrophilic polymer present in the permselective separation membrane, for example, when used in the medical field, excellent uremic substance diffusion performance is maintained over a range of low to medium polymers. At the same time, since albumin permeability can be suppressed, when used for hemodialysis, hemofiltration, hemodiafiltration, etc., good therapeutic results can be expected for improving the morbidity of renal failure patients. Moreover, it can be applied to an endotoxin removal filter for purifying dialysate by utilizing its high water permeability.
【図1】γ線照射前の膜中の親水性高分子ポリビニルピ
ロリドンの分子量分布を示す。FIG. 1 shows a molecular weight distribution of hydrophilic polymer polyvinylpyrrolidone in a film before γ-ray irradiation.
【図2】γ線照射後の膜の総括物質移動係数(Ko)と
ストークス半径の関係を表す。FIG. 2 shows the relationship between the overall mass transfer coefficient (Ko) of a film after γ-ray irradiation and the Stokes radius.
───────────────────────────────────────────────────── フロントページの続き (72)発明者 田中和実 滋賀県大津市園山1丁目1番1号 東レ株 式会社滋賀事業場内 ─────────────────────────────────────────────────── ─── Continuation of the front page (72) Inventor Minoru Tanaka, 1-1-1, Sonoyama, Otsu City, Shiga Prefecture Toray Co., Ltd. Shiga Plant
Claims (18)
てなる選択透過性分離膜において、分子量10万未満の親
水性高分子が親水性高分子全重量に対して10重量%以
上、50重量%以下含まれ、10万以上の親水性高分子
が親水性高分子全重量に対し、50重量%以上、90重
量%以下含まれていることを特徴とする選択透過性分離
膜。1. In a permselective separation membrane comprising a hydrophobic polymer and a hydrophilic polymer as main components, the hydrophilic polymer having a molecular weight of less than 100,000 is 10% by weight or more based on the total weight of the hydrophilic polymer. A permselective separation membrane comprising 50% by weight or less and 100,000 or more hydrophilic polymers in an amount of 50% by weight or more and 90% by weight or less based on the total weight of the hydrophilic polymers.
ることを特徴とする請求項1記載の選択透過性分離膜。2. The permselective separation membrane according to claim 1, wherein the hydrophobic polymer is a polysulfone resin.
ある請求項1記載の選択透過性分離膜。3. The permselective separation membrane according to claim 1, wherein the hydrophilic polymer is polyvinylpyrrolidone.
対して3重量%以上、15重量%以下である請求項1〜
3のいずれかに記載の選択透過性分離膜。4. The hydrophilic polymer content is 3% by weight or more and 15% by weight or less with respect to the hydrophobic polymer.
3. The permselective separation membrane according to any one of 3 above.
求項1〜4のいずれかに記載の選択透過性分離膜。5. The permselective separation membrane according to any one of claims 1 to 4, which is used as an artificial kidney.
てなる選択透過性分離膜において、分子量10万未満の親
水性高分子が親水性高分子全重量に対して10重量%以
上、50重量%以下含まれ、10万以上の親水性高分子
が親水性高分子全重量に対し、50重量%以上、90重
量%以下含まれた膜を不溶化処理してなることを特徴と
する選択透過性分離膜。6. A selective permeable separation membrane comprising a hydrophobic polymer and a hydrophilic polymer as main components, wherein the hydrophilic polymer having a molecular weight of less than 100,000 is 10% by weight or more based on the total weight of the hydrophilic polymer, A selection which is characterized in that a membrane containing 50% by weight or less and 100,000 or more hydrophilic polymers in an amount of 50% by weight or more and 90% by weight or less with respect to the total weight of the hydrophilic polymer is insolubilized. Permeable separation membrane.
重量%以上、15重量%以下である請求項6記載の選択
透過性分離膜。7. The content of insoluble matter is 2 with respect to the total weight of the film.
The permselective separation membrane according to claim 6, wherein the content is not less than 15% by weight and not more than 15% by weight.
15重量%以上、40重量%以下、親水性高分子60重
量%以上、85重量%以下由来である請求項6または請
求項7記載の選択透過性分離膜。8. The composition of the insolubilized product is derived from the hydrophobic polymer before insolubilization of 15% by weight or more and 40% by weight or less and the hydrophilic polymer of 60% by weight or more and 85% by weight or less. The selectively permeable separation membrane described.
ることを特徴とする請求項6〜8のいずれかに記載の選
択透過性分離膜。9. The permselective separation membrane according to claim 6, wherein the hydrophobic polymer is a polysulfone resin.
である請求項6〜9のいずれかに記載の選択透過性分離
膜。10. The permselective separation membrane according to claim 6, wherein the hydrophilic polymer is polyvinylpyrrolidone.
加剤を少なくとも含む製膜原液を用い、分子量の異なる
親水性高分子を2種類以上含有し、かつ、分子量10万
以上の親水性高分子の含有比率が該製膜原液全体に対し
て1.8重量%以上、20重量%以下であることを特徴
とする選択透過性分離膜の製造方法。11. A hydrophilic membrane having a molecular weight of 100,000 or more and containing two or more hydrophilic polymers having different molecular weights, using a stock solution for film formation containing at least a hydrophobic polymer and a hydrophilic polymer, a solvent, and an additive. The method for producing a permselective separation membrane, wherein the content ratio of the permeable polymer is 1.8% by weight or more and 20% by weight or less with respect to the entire membrane forming solution.
ある請求項11記載の選択透過性分離膜の製造方法。12. The method for producing a permselective separation membrane according to claim 11, wherein the hydrophobic polymer is a polysulfone resin.
である請求項11記載の選択透過性分離膜の製造方法。13. The method for producing a permselective separation membrane according to claim 11, wherein the hydrophilic polymer is polyvinylpyrrolidone.
の親水性高分子を含有し、かつ、該親水性高分子中、低
分子量成分が20重量%以上、70重量%以下である請
求項11〜13のいずれかに記載の選択透過性分離膜の
製造方法。14. A hydrophilic polymer containing two kinds of hydrophilic polymers different in weight average molecular weight by 5 times or more, and a low molecular weight component in the hydrophilic polymer is 20% by weight or more and 70% by weight or less. 11. The method for producing a permselective separation membrane according to any one of 11 to 13.
てストークス半径で少なくとも3nmの総括物質移動係
数が0.0025cm/min以上で、かつアルブミン
透過率が4%以下である選択透過性分離膜。15. A permselective separation membrane having a Stokes radius of at least 3 nm, an overall mass transfer coefficient of 0.0025 cm / min or more, and an albumin permeability of 4% or less in a diffusion performance test with dextran.
求項15記載の選択透過性分離膜。16. The permselective separation membrane according to claim 15, wherein the albumin permeability is 3% or less.
求項15記載の選択透過成分離膜。17. The permselective separation membrane according to claim 15, wherein the albumin permeability is 2% or less.
請求項15〜17のいずれかに記載の選択透過性分離
膜。18. The permselective separation membrane according to any one of claims 15 to 17, which is used as an artificial kidney.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP17100796A JP3617194B2 (en) | 1995-06-30 | 1996-07-01 | Permselective separation membrane and method for producing the same |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7-166461 | 1995-06-30 | ||
| JP16646195 | 1995-06-30 | ||
| JP17100796A JP3617194B2 (en) | 1995-06-30 | 1996-07-01 | Permselective separation membrane and method for producing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0970524A true JPH0970524A (en) | 1997-03-18 |
| JP3617194B2 JP3617194B2 (en) | 2005-02-02 |
Family
ID=26490827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP17100796A Expired - Lifetime JP3617194B2 (en) | 1995-06-30 | 1996-07-01 | Permselective separation membrane and method for producing the same |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3617194B2 (en) |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998052683A1 (en) * | 1997-05-19 | 1998-11-26 | Asahi Medical Co., Ltd. | Polysulfone-base hollow-fiber hemocathartic membrane and processes for the production thereof |
| JP2003510068A (en) * | 1999-09-30 | 2003-03-18 | ユニサーチ リミテツド | Method and apparatus for culturing cells |
| JP2004231650A (en) * | 2003-01-09 | 2004-08-19 | Toray Ind Inc | Mast cell stimulating factor-containing composition and blood purifier for removing the same |
| WO2006024902A1 (en) * | 2004-08-06 | 2006-03-09 | Asahi Kasei Medical Co., Ltd. | Polysulfone hemodialyzer |
| JP2008534274A (en) * | 2005-04-07 | 2008-08-28 | ガンブロ・ルンディア・エービー | Filtration membrane |
| JP2009160490A (en) * | 2007-12-28 | 2009-07-23 | Mitsubishi Rayon Eng Co Ltd | Method for producing porous membrane |
| JP2010506709A (en) * | 2006-10-18 | 2010-03-04 | ガンブロ・ルンディア・エービー | Hollow fiber membrane and method for producing hollow fiber membrane |
| US7922007B2 (en) | 2004-03-22 | 2011-04-12 | Toyo Boseki Kabushiki Kaisha | Separation membrane with selective permeability and process for producing the same |
| JP2011092928A (en) * | 2009-09-30 | 2011-05-12 | Toray Ind Inc | Separation membrane and separation membrane module |
| JPWO2011010690A1 (en) * | 2009-07-22 | 2013-01-07 | 三菱レイヨン株式会社 | Method for producing porous membrane |
| JP2014079687A (en) * | 2012-10-16 | 2014-05-08 | Asahi Kasei Chemicals Corp | Separation membrane and production method of the same |
| US9849427B2 (en) | 2003-11-17 | 2017-12-26 | Asahi Kasei Medical Co., Ltd. | Hollow fiber membrane for blood purification and blood purification apparatus using the same |
| EP3102314B1 (en) | 2014-02-06 | 2018-09-19 | Gambro Lundia AB | Membrane for blood purification |
| EP3102312B1 (en) | 2014-02-06 | 2018-09-26 | Gambro Lundia AB | Hemodialyzer for blood purification |
-
1996
- 1996-07-01 JP JP17100796A patent/JP3617194B2/en not_active Expired - Lifetime
Cited By (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6432309B1 (en) | 1997-05-19 | 2002-08-13 | Asahi Medical Co, Ltd | Polysulfone-base hollow-fiber hemocathartic membrane and processes for the production thereof |
| KR100351886B1 (en) * | 1997-05-19 | 2002-09-12 | 아사히 메디칼 가부시키가이샤 | Polysulfone-Base Hollow-Fiber Hemocathartic Membrane And Processes For The Production Thereof |
| WO1998052683A1 (en) * | 1997-05-19 | 1998-11-26 | Asahi Medical Co., Ltd. | Polysulfone-base hollow-fiber hemocathartic membrane and processes for the production thereof |
| JP2003510068A (en) * | 1999-09-30 | 2003-03-18 | ユニサーチ リミテツド | Method and apparatus for culturing cells |
| JP2004231650A (en) * | 2003-01-09 | 2004-08-19 | Toray Ind Inc | Mast cell stimulating factor-containing composition and blood purifier for removing the same |
| US9849427B2 (en) | 2003-11-17 | 2017-12-26 | Asahi Kasei Medical Co., Ltd. | Hollow fiber membrane for blood purification and blood purification apparatus using the same |
| US7922007B2 (en) | 2004-03-22 | 2011-04-12 | Toyo Boseki Kabushiki Kaisha | Separation membrane with selective permeability and process for producing the same |
| WO2006024902A1 (en) * | 2004-08-06 | 2006-03-09 | Asahi Kasei Medical Co., Ltd. | Polysulfone hemodialyzer |
| US8828225B2 (en) | 2004-08-06 | 2014-09-09 | Asahi Kasei Medical Co., Ltd. | Polysulfone hemodialyzer |
| JP2008534274A (en) * | 2005-04-07 | 2008-08-28 | ガンブロ・ルンディア・エービー | Filtration membrane |
| JP2010506709A (en) * | 2006-10-18 | 2010-03-04 | ガンブロ・ルンディア・エービー | Hollow fiber membrane and method for producing hollow fiber membrane |
| JP2009160490A (en) * | 2007-12-28 | 2009-07-23 | Mitsubishi Rayon Eng Co Ltd | Method for producing porous membrane |
| JPWO2011010690A1 (en) * | 2009-07-22 | 2013-01-07 | 三菱レイヨン株式会社 | Method for producing porous membrane |
| JP2011092928A (en) * | 2009-09-30 | 2011-05-12 | Toray Ind Inc | Separation membrane and separation membrane module |
| JP2014079687A (en) * | 2012-10-16 | 2014-05-08 | Asahi Kasei Chemicals Corp | Separation membrane and production method of the same |
| EP3102314B1 (en) | 2014-02-06 | 2018-09-19 | Gambro Lundia AB | Membrane for blood purification |
| EP3102312B1 (en) | 2014-02-06 | 2018-09-26 | Gambro Lundia AB | Hemodialyzer for blood purification |
| US10661230B2 (en) | 2014-02-06 | 2020-05-26 | Gambro Lundia Ab | Hemodialyzer for blood purification |
| US10661231B2 (en) | 2014-02-06 | 2020-05-26 | Gambro Lundia Ab | Membrane for blood purification |
| US11273416B2 (en) | 2014-02-06 | 2022-03-15 | Gambro Lundia Ab | Membrane for blood purification |
| US11273417B2 (en) | 2014-02-06 | 2022-03-15 | Gambro Lundia Ab | Hemodialyzer for blood purification |
| US11666868B2 (en) | 2014-02-06 | 2023-06-06 | Gambro Lundia Ab | Membrane for blood purification |
| US11666869B2 (en) | 2014-02-06 | 2023-06-06 | Gambro Lundia Ab | Hemodialyzer for blood purification |
| US12059658B2 (en) | 2014-02-06 | 2024-08-13 | Gambro Lundia Ab | Membrane for blood purification |
| US12059657B2 (en) | 2014-02-06 | 2024-08-13 | Gambro Lundia Ab | Hemodialyzer for blood purification |
Also Published As
| Publication number | Publication date |
|---|---|
| JP3617194B2 (en) | 2005-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100432464B1 (en) | Polysulfone Hollow Fiber Semipermeable Membrane | |
| EP1388364A1 (en) | Asymmetric porous films and process for producing the same | |
| EP0569229A1 (en) | High efficiency removal of low density lipoprotein-cholesterol from whole blood | |
| CN100457242C (en) | Improved Dialysis Membrane for Middle Molecule Removal | |
| JPWO2002009857A1 (en) | Modified hollow fiber membrane | |
| US6355730B1 (en) | Permselective membranes and methods for their production | |
| JP3617194B2 (en) | Permselective separation membrane and method for producing the same | |
| JP4061798B2 (en) | Semipermeable membrane for blood treatment and dialyzer for blood treatment using the same | |
| EP0750936B1 (en) | Permselective membranes and methods for their production | |
| JP3966481B2 (en) | Semipermeable membrane | |
| AU672856B2 (en) | High flux hollow fiber membrane | |
| JP5129962B2 (en) | Integral asymmetric membrane, method for producing the same and use thereof | |
| JP3366040B2 (en) | Polysulfone-based semipermeable membrane and method for producing the same | |
| JPWO2000027447A1 (en) | blood purifier | |
| JP4211169B2 (en) | Dialysis machine for blood treatment | |
| Lyman | Membranes | |
| EP0570232A2 (en) | Microporous polysulfone supports suitable for removal of low density lipoprotein-cholesterol | |
| JP2003175320A (en) | Method for manufacturing hollow fiber membrane | |
| JP4003982B2 (en) | Polysulfone-based selectively permeable separation membrane | |
| Courtney et al. | Polymer membranes | |
| JP3651121B2 (en) | Permselective separation membrane | |
| JP2003175321A (en) | Method for manufacturing hollow fiber membrane | |
| JP3489372B2 (en) | Perm-selective separation membrane | |
| JP2000153134A (en) | High performance blood purifying membrane | |
| JPH09308684A (en) | Selective separation membrane |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20041019 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20041101 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071119 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081119 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081119 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091119 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091119 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101119 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101119 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111119 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121119 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121119 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131119 Year of fee payment: 9 |
|
| EXPY | Cancellation because of completion of term |